Drug intelligence / Profile preview

tozinameran + elasomeran (Pfizer)

Development stage: Phase 4
Lead developer: Pfizer
Modality: Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intramuscular

Overview

BNT162b2 + mRNA-1273 is a heterologous mRNA COVID-19 vaccine regimen consisting of two distinct nucleoside-modified messenger RNA (mRNA) vaccines: tozinameran (BNT162b2; Comirnaty), developed by BioNTech and Pfizer, and elasomeran (mRNA-1273; Spikevax), developed by Moderna. Both vaccines are encapsulated in lipid nanoparticles and encode the prefusion-stabilized spike (S) glycoprotein of SARS-CoV-2. This heterologous prime-boost regimen is used to prevent COVID-19 by inducing robust neutralizing antibody and cellular (T-cell) immune responses against the SARS-CoV-2 virus. Clinical and observational studies have demonstrated that heterologous schedules combining these two mRNA vaccines are highly immunogenic and effective, though they may exhibit slightly higher reactogenicity compared to homologous regimens.

Other names: BNT162b2 + mRNA-1273Comirnaty + Spikevaxelasomeran + tozinameran

Beyond the preview

Go deeper on tozinameran + elasomeran (Pfizer).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tozinameran + elasomeran (Pfizer).